| Similar Articles |
|---|
 |
The Motley Fool
January 28, 2011
Luke Timmerman |
Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up.   |
The Motley Fool
October 19, 2006
Brian Lawler |
A Yawn and More Growth From Wyeth Investors, the numbers aren't all that new, but they are good. With its guidance of $3.12 to $3.18 in EPS for the year and a steadily increasing dividend, Wyeth is a good candidate for investors who want to get a start in this sector |
The Motley Fool
October 5, 2011
Arlene Weintraub |
Merck Fine-Tunes Biosimilars Strategy as FDA Guidelines Loom Merck readies itself to enter this potential new market. |
The Motley Fool
January 30, 2007
Brian Lawler |
Wyeth's Slow Growth Wyeth releases its 2006 financial results and guides for another year of slow growth. Investors, take note. |
The Motley Fool
December 20, 2007
Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. |
BusinessWeek
November 14, 2005
Gene G. Marcial |
Rivals Are Eyeing Wyeth Drugmaker Wyeth is the most attractive in the beleaguered pharma sector. |
The Motley Fool
April 20, 2005
Stephen D. Simpson |
Wyeth Looking Healthier Improving sales are helping this troubled drugmaker recover a little faster. Big pharma investors might see Wyeth as one of the more interesting growth and turnaround candidates in the industry. |
BusinessWeek
February 6, 2006
Amy Barrett |
Cracking The Whip At Wyeth Wyeth's R&D chief Robert Ruffolo imposed tough targets on scientists - and it's working. |
The Motley Fool
July 20, 2007
Billy Fisher |
Wyeth Keeps Working Its Magic The drugmaker's second-quarter boasts 12% earnings growth. Of particular promise was the reversal over first-quarter for its top seller, the antidepressant Effexor. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
The Motley Fool
July 20, 2006
Stephen D. Simpson |
Wyeth Wins Again Another respectable quarter and a decent pipeline make this pharmaceutical stock worth watching. |
The Motley Fool
January 31, 2006
Stephen D. Simpson |
Wyeth: Waiting on the Pipeline While Wyeth's growth today is modest, the late-stage pipeline could pay off. Investors, take note. |
The Motley Fool
July 25, 2008
Brian Orelli |
Generic Heartburn at Wyeth Revenue from its heartburn drug Protonix dropped 59% year over year after Teva Pharmaceuticals and Sun Pharmaceuticals launched their generic versions of the drug. |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
The Motley Fool
April 23, 2008
Brian Orelli |
Wyeth Recovers From Its Heartburn Wyeth deals with generic competition for one of its biggest drugs. |
BusinessWeek
January 29, 2007
Arlene Weintraub |
More Merger Mania Ahead For Pharma The scramble for new drugs is keeping companies on the prowl. |
The Motley Fool
October 6, 2006
Brian Lawler |
Wyeth Makes Investors Happy It's facing some challenges, but there's a lot for investors to like about this drug company. |
The Motley Fool
June 25, 2007
Brian Orelli |
Leading the Pack of Follow-On Drug Makers Generic drug maker Dr. Reddy's Laboratories is taking a huge risk to get ahead of the pack, but it's well worth the rewards of being in front of its competitors. Investors, take note. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
The Motley Fool
June 21, 2005
Brian Gorman |
Wyeth's Lower Dosage The company's planned sales-force cutback shows its resolve to increase efficiency. Investors, this pharmaceutical remains the one to watch. |
The Motley Fool
June 28, 2010
Luke Timmerman |
Future Biotech Winners Will Help Nurses Clean Up Less (Stuff) It's not enough anymore to prove your drug is safe and effective enough to pass muster with the FDA. Now it's also about proving a drug can generate savings and value for the health care system. |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
| Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
The Motley Fool
October 9, 2006
Brian Lawler |
The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field. |
The Motley Fool
January 28, 2010
Brian Orelli |
Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds. |
The Motley Fool
October 19, 2007
Billy Fisher |
Wyeth's Resilience Wyeth's latest quarter is an outstanding example of the drugmaker's consistency; the company reports solid results from all of its businesses, along with a 9% increase in sales. |
The Motley Fool
June 11, 2009
Brian Orelli |
The FTC Hates You, Too The agency weighs in (unhappily) on follow-on biologics. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
March 3, 2009
Brian Orelli |
Stop Worrying About Follow-On Biologics They're inevitable, but they won't hurt biotech as much as you might think. |
Managed Care
May 2004 |
Biologics Among Fastest Growers Managed care plans and pharmacy benefit managers can benefit from the strong generic presence in the market, but also face challenges relating to biotech drugs. |
The Motley Fool
August 18, 2010
Travers & Jayson |
Interested in Elan? Start Here! You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big. |
BusinessWeek
October 18, 2004
Catherine Arnst |
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma |
The Motley Fool
August 17, 2010
Travers & Jayson |
Interested in Cephalon ? Start Here! Every biotech company wants to discover the cure for cancer, Alzheimer's, or Wii knee. Every biotech investor hopes to catch the next Valeant Pharmaceuticals. |
The Motley Fool
April 20, 2007
Billy Fisher |
Many Ways to Feel Good About Wyeth The drugmaker's pipeline makes investors look forward to the next few quarters, too. |
Pharmaceutical Executive
December 1, 2008
Walter Armstrong |
The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future. |
The Motley Fool
August 17, 2010
Travers & Jayson |
Is Alexion Pharmaceuticals Burning Out? The first step toward finding a promising biotech company is not to figure out whether the science is any good, but to make sure that the company is financially healthy. |
Pharmaceutical Executive
March 1, 2009
Walter Armstrong |
Attack of the Monster Merger Just when you thought it was safe to go back into M&A, the mega merger returns. What's right about Pfizer-Wyeth, and what's scary. |
The Motley Fool
March 27, 2009
Brian Orelli |
Trading Up With the $95 From Genentech Genentech is gone; here's what you should replace it with. |
The Motley Fool
October 31, 2006
Brian Lawler |
A Look Inside the Biotech Haunted House Even after being warned of the risks, if you're still brave enough to come inside the biotech haunted house, realize that there are surprises. For example, the FDA will spook investors with calls for more clinical trials on drugs that appear to be a lock for approval. |
The Motley Fool
January 21, 2009
Brian Orelli |
A Copycat on the Prowl Teva Pharmaceutical announces it is partnering with Lonza to develop generic versions of biologics, called biosimilars, or follow-on biologics. |
The Motley Fool
February 17, 2011
Brian Orelli |
What Sanofi-Genzyme Means for the Rest of Biotech This is no time to celebrate. |
The Motley Fool
August 17, 2010
Travers & Jayson |
How Long Can Amylin Pharmaceuticals Last? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big. |
The Motley Fool
March 7, 2008
Brian Orelli |
A Heavy Price for Wyeth and Pfizer They're ordered to pay millions because their hormone therapies may carry a higher risk of breast cancer. |
BusinessWeek
November 29, 2004
Catherine Arnst |
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. |
The Motley Fool
July 12, 2004
Ben McClure |
Falling for Amgen Ahead of its second-quarter earnings release, the biotech giant looks good. |
Pharmaceutical Executive
October 1, 2005
Brad Miles |
Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies. |
Pharmaceutical Executive
November 1, 2011 |
Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk. |
The Motley Fool
June 21, 2011
Alexander Crawford |
Bullish Biotech: 5 Biotech Firms Making Great Strides These five biotech firms have just received great news. Should they be on your watch list? |
The Motley Fool
May 18, 2010
Brian Orelli |
What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout. |
